Key result
Gain of chromosome 1q was significantly associated with adverse overall survival in patients with Ewing tumours, doubling the relative hazard of failure (RHR 2, P=0.046).
Why the study?
Does the presence of specific chromosomal aberrations (gain of 1q, loss of 16q) predict adverse survival outcomes in patients with Ewing tumours?
Population
134 patients with skeletal and extraskeletal Ewing tumours, median age 13 years, 46% male, from four centers.
Comparison
Presence of specific chromosomal aberrations… vs Absence of the respective chromosomal aberrations.
Design
Cohort
Follow-up
median 5 years for surviving patients
Authors
Loading...
1q gain supports refined prognostication in Ewing tumours; hypothesis-generating and requires prospective validation before guiding therapy.
Cohort (n=134)
Yes
Does the presence of specific chromosomal aberrations (gain of 1q, loss of 16q) predict adverse survival outcomes in patients with Ewing tumours?
Hazard Ratio: 2
Absolute Event Rate: 46% vs 72%
p-value: p=0.046
Assessment of 1q and 16q copy numbers in Ewing tumours provides important prognostic information, identifying patients at higher risk of adverse outcomes.
Hattinger et al. (2002) conducted a cohort in Ewing tumours (n=134). Gain of chromosome 1q vs. No gain of chromosome 1q was evaluated on 5-year overall survival (RHR 2, p=0.046). Gain of chromosome 1q was significantly associated with adverse overall survival in patients with Ewing tumours, doubling the relative hazard of failure (RHR 2, P=0.046).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: